Latest Information Update: 16 Mar 2016
At a glance
- Originator Celltrion
- Developer Celltrion; Valneva; Yonsei University Health System
- Class Antibodies
- Mechanism of Action Immunomodulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Research Hepatitis B
Most Recent Events
- 16 Mar 2016 Early research development is ongoing in South Korea (Celltrion pipeline, March 2016)
- 31 Dec 2011 Early research in Hepatitis B (Treatment-resistant) in South Korea (unspecified route) before December 2011